Pentagon rescinds new testosterone screening policy without explanation
Pentagon rescinds new testosterone screening policy without explanation
五角大楼在未作解释的情况下撤销了新的睾酮筛查政策
Following Defense Secretary Pete Hegseth’s startling announcement in July that the US military would begin mandatory testosterone screening for personnel, the Pentagon released a clinical guidance document on September 2 outlining the new medically questionable policy. The next day, though, the clinical guidance document disappeared, as did an accompanying statement by spokesperson Sean Parnell. The withdrawal was first reported by Reuters.
继国防部长皮特·赫格塞斯（Pete Hegseth）7月份宣布美军将开始对人员进行强制性睾酮筛查这一令人震惊的消息后，五角大楼于9月2日发布了一份临床指导文件，概述了这项在医学上备受质疑的新政策。然而，仅仅过了一天，这份临床指导文件就消失了，发言人肖恩·帕内尔（Sean Parnell）随附的声明也一并撤下。路透社率先报道了此次撤回事件。
In a statement sent to Ars Technica, the Pentagon said that the document, titled “Clinical Guidance for Health and Human Performance Optimization,” had been temporarily rescinded on September 3 to allow for updates. “The Department remains committed to addressing hormone deficiencies, protecting the long-term health of its Service members, and enabling peak operational performance,” the Pentagon said. An interim guidance remains in effect, and “the final clinical guidance will be issued shortly,” it added. The Pentagon declined to provide more information regarding what was being updated about the guidance and why it needed to be updated so quickly after its release.
在发给《Ars Technica》的一份声明中，五角大楼表示，这份名为《健康与人体机能优化临床指南》的文件已于9月3日暂时撤回，以便进行更新。五角大楼称：“国防部仍致力于解决荷尔蒙缺乏问题，保护服役人员的长期健康，并实现最佳作战表现。”五角大楼补充说，一份临时指南仍然有效，“最终的临床指南将很快发布”。五角大楼拒绝提供更多信息，说明该指南具体更新了什么内容，以及为何在发布后如此迅速地需要进行更新。
Reuters reported that the rescinded guidelines called for men aged 30 and older to be screened through a questionnaire that could then trigger a blood test for testosterone levels and, if needed, testosterone hormone therapy. Women were also to be screened through a questionnaire, which could lead to treatment for hormonal imbalances.
据路透社报道，被撤回的指南要求对30岁及以上的男性进行问卷筛查，筛查结果可能触发睾酮水平的血液检测，并在必要时进行睾酮激素治疗。女性也将通过问卷进行筛查，这可能导致针对荷尔蒙失调的治疗。
Potentially harmful guidance
潜在的有害指南
In Hegseth’s July announcement, he claimed that the testing and potential treatment was for “restoring and optimizing” capabilities of military members, protecting their “longevity,” and “ensuring [they] have the biological foundation required to sustain the fight.” Health experts have criticized the screening as being potentially harmful. Neither the Endocrine Society nor the American Urological Association supports routine screening for low testosterone.
在赫格塞斯7月份的声明中，他声称这些检测和潜在的治疗是为了“恢复和优化”军人的能力，保护他们的“长寿”，并“确保他们拥有维持战斗所需的生物学基础”。健康专家批评这种筛查可能是有害的。内分泌学会（Endocrine Society）和美国泌尿外科协会（American Urological Association）均不支持对低睾酮进行常规筛查。
Dr. Jason Goldman, an internal medicine physician and immediate past president of the American College of Physicians, told Reuters: “Taking testosterone is not going to make you more manly, more strong, or a more robust individual. That’s just not how it works,” Goldman said. “It’s just bad policy all around.”
内科医生、美国医师学会（American College of Physicians）前任主席杰森·戈德曼（Jason Goldman）博士告诉路透社：“服用睾酮并不会让你变得更阳刚、更强壮或更健壮。事实并非如此，”戈德曼说，“这完全是一项糟糕的政策。”
Ars Technica previously published an explainer on testosterone screening and treatment. In it, we talked with Bradley Anawalt, the chief of medicine at the University of Washington Medical Center, who specializes in endocrinology and men’s health. He went over the evidence-based reasons against population-level screening. Overall, “We’re turning the clock back on rational health care,” Anawalt told Ars. “I’m worried about the ethics. I’m worried about the health consequences. I’m worried about unnecessary evaluations, incorrect assessments, and incorrect diagnoses that lead to inappropriate prescriptions of testosterone.”
《Ars Technica》此前曾发布过一篇关于睾酮筛查和治疗的解释文章。在文中，我们采访了华盛顿大学医学中心内科主任、内分泌学和男性健康专家布拉德利·阿纳沃尔特（Bradley Anawalt）。他详细阐述了反对进行群体性筛查的循证理由。阿纳沃尔特告诉《Ars》：“总的来说，我们正在让理性的医疗保健开倒车。我担心其中的伦理问题，担心对健康的影响。我担心不必要的评估、错误的评估以及导致不当开具睾酮处方的错误诊断。”
Risks of conventional testosterone replacement therapy include decreased fertility, high red blood cell counts, acne, increased prostate size, and sleep apnea. Higher doses are associated with higher risks of cardiovascular disease and prostate cancer.
常规睾酮替代疗法的风险包括生育能力下降、红细胞计数升高、痤疮、前列腺增大和睡眠呼吸暂停。较高剂量与心血管疾病和前列腺癌的风险增加有关。